Pell Bio-Med Technology Co., Ltd. (TPE:6949)
Taiwan · Delayed Price · Currency is TWD 54.40
+1.30 (2.45%)
Sep 17, 2026, 1:30 PM CST
Pell Bio-Med Technology Revenue
Pell Bio-Med Technology had revenue of 8.95M TWD in the quarter ending June 30, 2026, with 52.47% growth. This brings the company's revenue in the last twelve months to 28.93M, up 5.45% year-over-year. In the year 2025, Pell Bio-Med Technology had annual revenue of 31.42M with 60.07% growth.
Revenue (ttm)
28.93M
Revenue Growth
+5.45%
P/S Ratio
2,464.25
Revenue / Employee
n/a
Employees
n/a
Market Cap
71.29B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.42M | 11.79M | 60.07% |
| Dec 31, 2024 | 19.63M | 1.60M | 8.86% |
| Dec 31, 2023 | 18.03M | 876.00K | 5.11% |
| Dec 31, 2022 | 17.16M | 3.18M | 22.75% |
| Dec 31, 2021 | 13.98M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sunmax Biotechnology | 2.19B |
| EirGenix | 1.21B |
| Ever Supreme Bio Technology | 1.08B |
| TaiMed Biologics | 619.49M |
| Medigen Vaccine Biologics | 573.85M |
| Oneness Biotech | 153.78M |
| ACRO Biomedical | 52.76M |
| Gongwin Biopharm Holdings | 42.22M |